2024 Mid-Year Myeloma Review with Paul Richardson, MD, Dana Farber Cancer Institute

Multiple myeloma mid-year progress with Dr. Paul Richardson of Dana FarberПодробнее

mPatient Myeloma Radio: Dr. Paul Richardson, MD, Dana-Farber Cancer InstituteПодробнее

Mezigdomide (CC-92480) | Paul Richardson, MD | ASH 2022Подробнее

New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24Подробнее

SARCLISA® (isatuximab) Update | Paul Richardson, MD | IMS 2022Подробнее

HealthTree Podcast for Multiple Myeloma: Paul Richardson, MD, Dana FarberПодробнее

Myeloma Crowd: Paul Richardson, MD, Dana Farber Cancer InstituteПодробнее

Myeloma Crowd Radio: Paul Richardson, MD, Dana Farber Cancer InstituteПодробнее

Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее

HealthTree Podcast for Multiple Myeloma: Paul Richardson, MD, Dana FarberПодробнее

Mezigdomide Plus Dexamethasone in RRMM: CC-92480-MM-002 Trial Results| Paul Richardson, MD |ASH 2023Подробнее

Multiple Myeloma: Novel Agents | Dana-Farber Cancer InstituteПодробнее

Myeloma Determination Study | Paul Richardson, MD | IMS 2022Подробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Multiple Myeloma: Study identifies genes as potential targets | Dana-Farber Cancer InstituteПодробнее

CELMoDs® Mezigdomide | Paul Richardson, MD | IMS 2022Подробнее

What are new treatment options for newly-diagnosed multiple myeloma patients? Dr. Paul G. RichardsonПодробнее

Risk Stratification for Smoldering Myeloma | Irene Ghobrial, MD | IMS 2024Подробнее

Treatment Options For Frail Patients at Early Relapse | Paul Richardson, MD | IMS 2023Подробнее